【美股财报】Intra-Cellular Therapies Inc 2024年度报告.pdf

AK112 to validate its potential as next-generation IO therapy

Access to oncology combination therapies in Europe moving forward

OS Therapies Inc 2025年季度报告

Taysha Gene Therapies Inc美股招股说明书(2025-05-28版)

Taysha Gene Therapies Inc 2024年度报告

BioRestorative Therapies Inc 2024年度报告

Medical Rationale Supporting Patient Access To Novel Oncology Combination Therapies

Considerations for the use of anthelminthic therapy for the treatment of neurocysticercosis